Loading...
•
Jun 30
GoodRx Q2 2025 Earnings Report
GoodRx reported its financial results for the second quarter of 2025, with revenue and Adjusted EBITDA Margin in line with previous guidance, and a significant increase in Pharma Manufacturer Solutions revenue.
Key Takeaways
GoodRx delivered a solid financial quarter in Q2 2025, with total revenue increasing 1% year-over-year to $203.1 million. The company achieved a net income of $12.8 million and an Adjusted EBITDA of $69.4 million, demonstrating continued year-over-year Adjusted EBITDA Margin growth. While facing headwinds in prescription transactions and subscriptions, the Pharma Manufacturer Solutions segment showed strong growth, increasing 32% year-over-year.
Total revenue for Q2 2025 increased by 1% year-over-year to $203.1 million.
Net income for the quarter was $12.8 million, with a net income margin of 6.3%.
Adjusted EBITDA reached $69.4 million, resulting in an Adjusted EBITDA Margin of 34.2%.
Pharma Manufacturer Solutions revenue saw a significant 32% increase year-over-year, reaching $35.0 million.
GoodRx
GoodRx
GoodRx Revenue by Segment
Revenue by Segment
Prescription Transactions Revenue
CapyFin.comSubscription Revenue
CapyFin.comPharma Manufacturer Solutions Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
For the full year 2025, GoodRx anticipates an increase in total revenue from 2024, with Q3 revenue expected to be lower than Q4. Despite lowering revenue projections due to external factors like the Rite Aid bankruptcy and volume reduction in an integrated savings program, the company expects full-year Adjusted EBITDA to be in the range of $265 million to $275 million, representing 2% to 6% growth compared to 2024.
Positive Outlook
- Full year 2025 total revenue is expected to increase from 2024.
- Full year Adjusted EBITDA is projected to be between $265 million and $275 million.
- Adjusted EBITDA growth is expected to be between 2% and 6% compared to 2024.
- Pharma manufacturer solutions are expected to continue performing at similar or higher levels throughout the rest of 2025.
- The core business remains strong, and the Adjusted EBITDA range encompasses a portion of the previous range, indicating effective strategic initiatives and operating efficiencies.
Challenges Ahead
- Q3 revenue is expected to be lower than Q4.
- Estimated impact from the Rite Aid bankruptcy is included in guidance.
- Volume reduction in one of the integrated savings programs is included in guidance.
- Combined, Rite Aid bankruptcy and volume reduction are expected to result in approximately $35 million to $40 million of estimated revenue loss in 2025.
- Lowering revenue expectations due to external factors is acknowledged as disappointing.